Summit Therapeutics (SMMT) Other Non Operating Income (2019 - 2023)

Summit Therapeutics' (SMMT) quarterly Other Non Operating Income came in at $419000.0 in Q1 2023, up 0.72% on a QoQ basis from $416000.0 in Q3 2020.

Summit Therapeutics (SMMT) Other Non Operating Income (2019 - 2023) Analysis & Trends

Summit Therapeutics (SMMT) has 3 years of Other Non Operating Income data on file, last reported at $419000.0 in Q1 2023.

Quarterly Other Non Operating Income changed N/A year-over-year to $419000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $419000.0 (changed N/A YoY) and the FY2023 annual result came in at $419000.0, changed N/A from the prior year.
Other Non Operating Income advanced to $419000.0 in Q1 2023, from $416000.0 in the prior quarter.
In the past five years, Other Non Operating Income ranged from a high of $419000.0 in Q1 2023 to a low of -$75000.0 in Q3 2019.
A 3-year average of $253333.3 and a median of $416000.0 in 2020 frame the typical range for Other Non Operating Income.
The widest YoY moves for Other Non Operating Income: up 654.67% in 2020, down 654.67% in 2020.
Tracing SMMT's Other Non Operating Income over 3 years: stood at -$75000.0 in 2019, then soared by 654.67% to $416000.0 in 2020, then rose by 0.72% to $419000.0 in 2023.
The last three Other Non Operating Income figures came in at $419000.0 (Q1 2023), $416000.0 (Q3 2020), and -$75000.0 (Q3 2019), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Summit Therapeutics	10.59 Bn	9.90 Bn	-

Download Data